Across its top 20 institutional holders, TBPH's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 11/100, avg. turnover score 45/100).

Quarterly Activity

Recent Activity

+$491.6M

Total Buy Value

$199.5M

Total Sell Value

New buy35

Trim48

Add60

Sold out34

Net Buyers

Net Sellers

Smart Money Convergence

TBPH does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

Filings (90d)

$218K

Total Est. Value

13K shares

Planned Shares

Last Filed 2026-06-15

Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
Farnum Rhonda	Officer	2026-06-15	13K shares	$218K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

CUSIP

G8807B106, 88338T104

FAQ

Who are the top institutional investors holding Theravance Biopharma, Inc. (TBPH)?

Major stakeholders currently include Madison Avenue Partners, LP ($154.4M), Weiss Asset Management LP ($121.0M), Newtyn Management, LLC ($78.6M). Based on the latest 13F filings, there are a total of 174 tracked investment funds and institutions maintaining positions in TBPH.

What is the overall institutional sentiment toward TBPH recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $103.2M, driven by 95 managers accumulating shares while 82 reduced their exposure.

Which institutions have been selling or reducing their TBPH positions?

In the latest period, 48 funds trimmed their holdings, and 34 managers completely exited their positions. The aggregate reported sell value was $199.5M.

Are there any notable investors adding TBPH to their portfolios?

Yes, buying activity remains notable. 35 institutions opened new positions in {ticker}, and 60 existing holders added to their shares. The total reported buy value for the quarter amounted to $491.6M.